Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference
Rhea-AI Summary
Rigel (Nasdaq: RIGL) will present a company overview at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 8:30 am ET. Dean Schorno, chief financial officer, will deliver the presentation.
Investors can access a live webcast and archived recording via the Investor Relations section of Rigel's website at www.rigel.com; attendees are advised to connect to the site before the start time to allow for any software downloads.
Positive
- None.
Negative
- None.
News Market Reaction – RIGL
On the day this news was published, RIGL gained 2.82%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed moves, with RZLT up 14.29% and in momentum scanning down about 5%, while others like NRIX fell 2.85% and TERN gained 4.3%, suggesting stock-specific rather than sector-wide drivers.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 26 | Conference appearance | Neutral | +2.8% | Announcement of Piper Sandler healthcare conference presentation webcast access. |
| Nov 17 | Clinical data update | Positive | +1.4% | Publication of final five‑year REZLIDHIA Phase 2 data in AML. |
| Nov 12 | Conference appearance | Neutral | +5.2% | Jefferies Global Healthcare Conference presentation with webcast access. |
| Nov 04 | Earnings and update | Positive | -7.4% | Strong Q3 2025 financials and raised 2025 revenue guidance. |
| Nov 03 | Conference abstracts | Positive | -2.9% | Announcement of one oral and four poster presentations at ASH. |
Conference and clinical data announcements have often coincided with positive moves, while strong earnings and major data updates have occasionally seen negative reactions.
This announcement fits Rigel’s pattern of active investor engagement, following multiple conference presentations and data disclosures. Recent news included strong Q3 2025 results with total revenue of $69.5M, net product sales of $64.1M, and raised full‑year revenue guidance to $285–$290M. Clinical updates highlighted five‑year REZLIDHIA data in R/R mIDH1 AML and new R289 results headed to ASH. Against this backdrop, another healthcare conference presentation extends ongoing outreach but adds limited new fundamental information.
Market Pulse Summary
This announcement highlights Rigel’s participation in the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025 at 8:30 am ET, extending its pattern of active engagement with investors. Recent history shows a mix of conference, earnings, and clinical updates, with some strong financial and data milestones already disclosed. Investors tracking this event may focus on any incremental color versus prior guidance, the emphasis on hematologic disorders and cancer, and how management frames upcoming clinical and commercial priorities.
Key Terms
hematologic disorders medical
AI-generated analysis. Not financial advice.
To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
646.461.6387
david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-to-present-at-the-piper-sandler-37th-annual-healthcare-conference-302626268.html
SOURCE Rigel Pharmaceuticals, Inc.
